🧠 2025 Alzheimer’s Disease Facts & Figures (Alzheimer’s Association)

Published In: Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association
Date: May 2025
Authors: Alzheimer’s Association
Link to Study: Alzheimer’s Association 2025 Report

---

Summary

This annual report compiles the latest statistics and insights on Alzheimer’s disease in the U.S., including prevalence, care costs, and new treatments. The 2025 edition highlights a shift in public opinion toward supporting early diagnosis, driven by the availability of new drugs that may slow disease progression. It also introduces revised diagnostic criteria that use biomarkers to detect Alzheimer’s even before symptoms appear.

---

Key Takeaways

✅ Over 6.9 million Americans age 65+ live with Alzheimer’s, expected to rise significantly by 2060.
✅ New FDA-approved drugs (lecanemab and donanemab) can slow progression if diagnosed early.
✅ Public support is growing for early detection, especially with the availability of blood-based biomarker tests.
✅ Early diagnosis helps individuals and families plan for care, finances, and safety.
✅ Many Americans are still unaware of or hesitant about early testing due to stigma or misunderstanding.

---

Why It Matters for You

Catching Alzheimer’s early opens the door to new treatments that can slow its impact and give families more time to plan. Knowing the signs and talking to a doctor about testing—especially with a family history—can make a big difference.

---

Citation

Alzheimer’s Association. (2025). 2025 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia, 21(5). https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf